Impact of line-1 hypomethylation on the clinicopathological and molecular features of colorectal cancer patients

Tai Chuan Kuan, Pei Ching Lin, Shung Haur Yang, Chun Chi Lin, Yuan Tzu Lan, Hung Hsin Lin, Wen Yi Liang, Wei Shone Chen, Jen Kou Lin, Jeng Kai Jiang*, Shih Ching Chang

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Recent studies suggest that aberrant DNA methylation might occur early and commonly in colorectal tumorigenesis. In 111 normal subjects, the mean LINE-1 methylation level of peripheral blood was 81.0 ± 5.7%. Of 143 colorectal cancer (CRC) patients, the mean level of LINE-1 methylation was 60.5 ± 12.5%. We defined below 60% as cut-off value of LINE-1 hypomethylation, and 93 cases (65.0%) had LINE-1 hypomethylation in the tumor tissue. LINE-1 hypomethylation was not associated with any other clinical features. There was a trend that LINE-1 hypomethylation tumors were associated with advanced disease, but it did not reach statistical significance. There was no significant association between mutations of 12 genes, MSI-high, EMAST, and LINE-1 hypomethylation level. The median follow-up was 61.2 months. Five-year disease-free survival (DFS) and overall survival curves of patients with LINE-1 hypomethylation tumors were significantly lower than those of patients with normal LINE-1 methylation tumors (p = 0.032 and 0.001, respectively). Multivariate analysis showed that only TNM staging was an independent prognostic factor for CRC patients including DFS and overall survival (OS). LINE-1 did not impact patients’ outcomes in multivariate analysis including DFS and OS. In conclusion, LINE-1 hypomethylation is marginally related to advanced stage CRC and impacts patients’ outcomes in univariate analysis.

Original languageEnglish
Article numbere0197681
JournalPLoS ONE
Volume13
Issue number5
DOIs
StatePublished - May 2018

Fingerprint

Dive into the research topics of 'Impact of line-1 hypomethylation on the clinicopathological and molecular features of colorectal cancer patients'. Together they form a unique fingerprint.

Cite this